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ABSTRACT
Multiple system atrophy (MSA) is a sporadic neurodegenerative disease of the central and auto-
nomic nervous system. Because no drug treatment consistently beneﬁts MSA patients, neuropro-
tective strategy using mesenchymal stem cells (MSCs) has a lot of concern for the management of
MSA. In this study, we investigated the safety and efﬁcacy of intra-arterial administration of MSCs
via internal carotid artery (ICA) in an animal model of MSA. The study was composed of feasibility
test using a 310 and 350 of a standard dose of MSCs (4 3 107 MSCs) and efﬁcacy test using a
30.2, 32, and 320 of the standard dose. An ultrasonic ﬂow meter and magnetic resonance imag-
ing (MRI) showed that no cerebral ischemic lesions with patent ICA blood ﬂow was were observed
in animals receiving a 310 of the standard dose of MSCs. However, no MSA animals receiving a
350 of the standard dose survived. In efﬁcacy test, animals injected with a 32 of the standard
dose increased nigrostriatal neuronal survival relative to a 30.2 or 320 of the standard dose. MSA
animals receiving MSCs at30.2 and32 concentrations of the standard dose exhibited a signiﬁcant
reduction in rotation behavior relative to 320 of the standard dose of MSCs. Cerebral ischemic
lesions on MRI were only observed in MSA animals receiving a320 of the standard dose. The pres-
ent study revealed that if their concentration is appropriate, intra-arterial injection of MSCs is safe
and exerts a neuroprotective effect on striatal and nigral neurons with a coincidental improvement
in motor behavior. STEM CELLS TRANSLATIONAL MEDICINE 2017;6:1424–1433
SIGNIFICANCE STATEMENT
Multiple system atrophy (MSA) is a sporadic neurodegenerative disease of the central and auto-
nomic nervous system. Because no drug treatment consistently benefits MSA patients, neuro-
protective strategy using mesenchymal stem cells (MSCs) has a lot of concern for the
management of MSA. Our study has provided important details that intra-arterial administration
of MSCs is feasible and efficient administration route, resulting in improvement of neuronal via-
bility and behavioral performance in a double toxin-induced MSA model. The present data may
advance clinical applications of intra-arterial route of MSC administration in patients with MSA.
INTRODUCTION
Multiple system atrophy (MSA) is a sporadic neu-
rodegenerative disease of the central and auto-
nomic nervous system, and its clinical features
include any combination of autonomic failure, par-
kinsonism, and pyramidal signs. Pathologically,
MSA is regarded as a unique entity within the
spectrum of oligodendrogliopathy, with extensive
a-synuclein-positive glial cytoplasmic inclusions,
and leading to striatonigral degeneration, olivo-
pontocerebellar degeneration, astrogliosis, and
microgliosis [1]. Because of grave prognosis, many
clinical studies have been conducted to modify
disease progression in MSA, such as trials involving
growth hormone, immunoglobulin, monoamine
oxidase type B (MOB-B) inhibitor, or rifampicine
[2]. However, these trials have failed to achieve
neuroprotective efﬁcacy.
Mesenchymal stem cells (MSCs) are multipo-
tent stem cells present in adult bone marrow that
are capable of differentiating into various cell types
under appropriate conditions. Additionally, MSCs
secrete various cytotropic factors including neuro-
trophic growth factors, chemokines, cytokines, and
extracellular matrix protein, which in turn, exert
neuroprotective effects [3, 4]. Our previous studies
show that MSCs have potent neuroprotective
effects in animal models of parkinsonian disorders
through modulation of neuroinﬂammation,
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inhibition of apoptotic cell death, increases in neurogenesis and
neuronal differentiation, and enhancement of autophagy [5–8]. In
addition, MSC exert a neuroprotective effect in animal model of
MSA [9]. Moreover, we recently demonstrated in investigator initi-
ated trials that intra-arterial administration of MSCs delays progres-
sion of neurological deﬁcits assessed clinically and radiologically in
patients with MSA [10].
Of several potential delivery routes, intra-arterial administra-
tion of MSCs has received attention because this approach
increases cell homing to the brain by circumventing the pulmo-
nary circulation and thus leads to enhanced therapeutic outcomes
[11–13]. However, cerebral ischemia related to intra-arterial cell
infusion has been reported, although the complications related to
intra-arterial administration of stem cells seem to depend on the
infusion technique, cell dose, and infusion velocity [14, 15]. There-
fore, a careful optimization of the intra-arterial infusion proce-
dures, especially with regard to cell dose is required before
pharmacotherapeutic development of stem cell therapy. In the
present study, we investigated the safety and efﬁcacy of intra-
arterial administration of MSCs at different cell doses using a
double-toxin-induced animal model of MSA.
MATERIALS AND METHODS
Animal Study and Experimental Composition
To create a double toxin-induced animal model of MSA, adult
male or female Sprague Dawley rats (200–220 g) were injected
with 6-hydroydopamine (6-OHDA, Sigma, St. Louis, MO, USA) and
quinolinic acid (QA, Sigma) [16]. 6-OHDA (8 lg/4 ll) was injected
by stereotaxic injection into the left medial forebrain bundle (A
22.2, L1 1.5 relative to bregma, V28.0 relative to the dura, and
with the tooth bar 4.5 mm above the interaural line). Three–four
weeks after 6-OHDA injection, a total of 150 nmol/4 ml QA was
stereotaxically injected into two sites of the left striatum (A11.4/
13.0, L 13.5/13.0 relative to bregma, V 24.0 relative to the
dura, and with the tooth bar 4.5 mm above the interaural line). All
injections were made over 1 minute, and the needle was left in
place for a further 2 minutes before being slowly withdrawn. The
rats were randomly divided into three groups (n5 5; each group):
(1) the control group; (2) the normal saline-treated group; (3) the
MSC-treated group. The animal study was composed of two con-
secutive experiments; the ﬁrst experiment was to test feasibility
and distribution of intra-arterially injected MSCs and the second
experiment was to exam efﬁcacy of different doses of MSCs. The
animal work was approved by the Institutional Animal Care and
Use Committees of Yonsei University.
MSC Transplantation
One week after QA injection, MSCs were injected into the ICA
or tail vein. Based on MSC concentration used by previous clini-
cal trials [10], a concentration of 4 3 107 cells/60 kg was
selected as a standard dose of MSCs. The cell dose of human
MSCs (hMSCs) used in the ﬁrst experiment was a 310 and 350
of the standard dose of MSCs. Then, a 30.2, 32, and 310 of
the standard dose were used in the second experiment. For ICA
injection, animals were anesthetized with 30% isoﬂurane.
According to the previous experiment [14], the common carotid
artery (CCA) was exposed and the external carotid artery and
pterygopalatine artery were ligated. MSCs in 100 ll of solvent
(Corestem, Inc., Seoul, Korea) were injected via a 33G micronee-
dle into the CCA with preserved blood ﬂow in the CCA and ICA
for 30 seconds and bleeding was controlled by application of
bioabsorbable Gelfoam (Pﬁzer, New York, NY, USA) at the injec-
tion site for 5 minutes. Pressure was maintained at the injection
site until bleeding ceased and then ﬁxed external carotid artery
and pterygopalatine artery opened.
Isolation of hMSCs
Bone marrow aspirates (10 ml) were obtained from the iliac crests
of human donors. The mononuclear cell layer was isolated by Cor-
estem, Inc. At passage 6, hMSCs were injected into rats via the
CCA or tail vein.
Fluorescence Activated Cell Sorting Analysis
The characterization of hMSCs was evaluated by ﬂuorescence acti-
vated cell sorting (FACS) analysis. Brieﬂy, cell suspensions were
washed twice with phosphate buffered saline (PBS, Sigma) con-
taining 0.1% bovine serum albumin (BSA, Sigma). For direct
assays, 1 3 105 cells/ml were incubated with ﬂuorescein isothio-
cyanate (FITC)-conjugated CD34 and CD45 (negative markers) as
well as CD105 and anti-human CD73 (positive markers) at 48C for
30 minutes, and then washed twice with PBS containing 0.1%
BSA. The cells were analyzed by cytometric analysis using an EPICS
XL ﬂow cytometer (Becton-Dickinson, San Diego, CA, USA) with
EXPO32 software.
Behavioral Test
Three weeks after the 6-OHDA lesion, apomorphine-induced rota-
tion was assessed (apomorphine hydrochloride, 0.5 mg/kg S.C.
dissolved in sterile water; Sigma). Only animals showing a mean of
6 contralateral rotations/minutes over 30 minutes following the
administration of apomorphine were retained. Behavioral test
was repeated 2–3 weeks after striatal lesioning with QA as well as
1, 2, and 3 weeks after MSC transplantation.
Tissue Preparation
For immunohistochemistry, rats were perfused with a saline solu-
tion containing 0.5% sodium nitrate and heparin (10 U/ml) and
ﬁxed with 4% paraformaldehyde dissolved in 0.1 M phosphate
buffer (PB) (50 ml/rat) at 8 weeks after the ﬁrst injection. Brains
were removed from the skulls, post-ﬁxed overnight in buffered
4% paraformaldehyde at 48C, and stored in a 30% sucrose solution
for 1–2 days at 48C until they sank. Coronal sections (30 lm) were
obtained and stored in tissue stock solution (30% glycerol, 30%
ethylene glycol, 30% three times distilled water, 10% 0.2 M PB) at
48C until use.
Immunohistochemistry
The coronal brain sections (4 lm thick) were rinsed twice in PBS
and incubated in 0.2% Triton X-100 for 30 minutes at room tem-
perature (RT). They were rinsed three times and blocked with 0.5%
BSA in 31 PBS. After blocking, sections were incubated at 48C
overnight with the following primary antibodies: mouse anti-
tyrosine hydroxylase (TH; 1:2,000; Pel-freez, Rogers, AR, USA), rab-
bit anti-dopamine- and cAMP-regulated neuronal phosphoprotein
(DARPP-32) (1:7,500; Abcam, Cambridge, MA, USA), rabbit anti-
Annexin V (1:500; Abcam, Cambridge, MA, USA), mouse anti-NeuN
(1:500; Abcam, Cambridge, MA, USA), or mouse anti-nuclear
matrix (NuMA; 1:100; Calbiochem, San Diego, CA, USA). Following
overnight incubation, the brain sections were rinsed three times
with 0.5% BSA in 31 PBS (10 minutes/rinse) and incubated with
the appropriate biotinylated secondary antibody and avidin–biotin
complex (Elite Kit; Vector Laboratories, Burlingame, CA, USA) for 1
hour at RT. Bound antibodies were visualized by incubating the
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sections with 0.05% diaminobenzidine–HCl (DAB, Dako, carpinte-
ria, CA, USA) and 0.003% hydrogen peroxide in 0.1 M PB. The brain
sections were rinsed with 0.1 M PB for DAB inhibition. Immuno-
stained cells were analyzed by bright-ﬁeld microscopy and viewed
under a Zeiss LSM 780 confocal imaging system (Zeiss, Jena, Thurin-
gia, Germany). To analyze the localizations of antigens in double-
stained samples, immunoﬂuorescence images were created from
the same tissue sections and merged using the Zeiss ZEN software
(Zeiss).
MSC Labeling for In Vivo Fluorescent Imaging
MSCs were labeled with NEO-LIVETM-Magnoxide675 (Biterials,
Seoul, South Korea), a ﬂuorescent magnetic nanoparticle used for
in vivo ﬂuorescent imaging. NEO-LIVETM-Magnoxide675 nanopar-
ticles were prepared according to the manufacturer’s protocol
and MSCs were incubated for 24 hours with labeling solution con-
taining NEO-LIVETM-Magnoxide 675 at a concentration of 0.4 mg/
ml in cultured media. Before animal injection, labeled MSCs were
analyzed by ﬂuorescence microscopy.
Optical In Vivo Imaging System and Magnetic
Resonance Imaging
For ﬂuorescence images, animals were anesthetized with 30%
isoﬂurane and images obtained using an Spectrum in vivo imag-
ing system (IVIS; Caliper Lifesciences, Hopkinton, Massachusetts,
USA) for data acquisition and analysis at 1 day, 3 days, 1 week, 2
weeks, 4 weeks, and 8 weeks after MSC transplantation. For mag-
netic resonance imaging (MRI), animals were anesthetized with
30% isoﬂurane, and images were obtained using a BioSpec 94/20
USR MRI (Bruker BioSpin, Ettlingen, Germany) for data acquisition
and analysis 1 week after MSC transplantation. The in vivo imag-
ing parameters were: (1) a three-dimensional T2*-weighted gra-
dient echo sequence with repetition time (TR)5 2,500 ms and
echo time (TE)5 24 ms for transverse sections of the brain, (2) a
T2-weighted two-dimensional spin echo sequence with
TR5 3,151 ms and TE5 24 ms. The MR angiography (MRA) scan
was performed under a time of ﬂight (TOF) sequence technique
(TR5 18.0 ms, TE5 4.0 ms, ﬂip angle (FA)5 808, slice
thickness5 0.35 mm, ﬁeld of view (FOV)5 40 mm 3 40 mm,
and matrix5 2563 256).
Figure 1. Flow cytometric analysis of human mesenchymal stem cells, showing positive markers (A) and negative markers (B).
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Ultrasonic Blood Flow Measurement
For operative procedures, animals were anesthetized with 10%
isoﬂurane in a mixture of 70% N2O and 30% O2. Anesthesia was
maintained with 2% isoﬂurane. During operative procedures,
body temperature was monitored continuously with a rectal
probe and maintained at 37.06 0.28C using a homeothermic
blanket control unit and a heating pad (Harvard Apparatus,
Holliston, MA, USA). A midline cervical incision was made, and
Figure 2. Evaluation of internal carotid artery (ICA) ﬂow and cerebral ischemia following intra-arterial injection of a 310 of the standard.
(A): An ultrasonic ﬂow meter showed that the ICA blood ﬂow was well preserved in animals receiving MSCs. (B): No occlusive lesion of the
ICA was observed at a310 of the standard dose on magnetic resonance angiography. (C): No hyperintense signals were observed in the brain
parenchymal of animals receiving MSCs on T2-weighted magnetic resonance imaging. Arrow indicates striatal lesion induced by 3-
nitroproprionic acid (3-NP). (D): Immunohistochemical analysis showed that MSC treatment signiﬁcantly decreased the number of TH-
positive and DARPP-32-positive neurons in the striatum (upper panel) and the substantia nigra (lower panel) of double-toxin treated animals
(each group, n5 5). Scale bar represents 200 mm. (E): Behavior performance in MSA animals receiving MSCs. The MSA animals receiving310
standard doses of MSCs showed signiﬁcantly the number of rotations after apomorphine injection compared with placebo-treated MSA ani-
mals (each group, n5 10). The data are presented as the means6 SE. *, p< .05; **, p< .01. Abbreviations: DARPP-32, dopamine- and
cAMP-regulated neuronal phosphoprotein; MSA, multiple system atrophy; MSC, mesenchymal stem cell; 6-OHDA, 6-hydroydopamine; QA,
quinolinic acid; TH, tyrosine hydroxylase.
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the left CCA was carefully dissected under a surgical micro-
scope. An ultrasonic Doppler ﬂow probe (MA0.7PSB; Transonic
Instruments, Ithaca, NY, USA) was placed around midportion of
the CCA. Carotid blood ﬂow was obtained with a Transonic
TS420 Blood Flow Meter (Transonic Instruments, Ithaca, NY,
USA) and an iWorx IX-304T data acquisition system (iWorx Sys-
tems, Inc., Dover, NH). Computer-based analysis by iWorx Lab-
scribe 2 software (version 2.045000) was performed to
minimize any bias when assessing results. CCA baseline ﬂow
was measured for 3 minutes.
Stereological Cell Counts
The total number of cells in the substantia nigra (SN), striatum,
and frontal cortex was estimated using an optical fractionator
and unbiased stereology of stained cells, as previously
described [17]. The sections used for counting covered the
entire SN from the rostral tip of the pars compacta back to the
caudal end of the pars reticulata. This generally yielded 8–9
sections in a series. Sampling was performed using the Olym-
pus BX51 microscope (Olympus, Tokyo, Japan), and the SN was
delineated at 31.25 objective. A counting frame (60%, 35
frames, 650 lm2) was placed randomly on the ﬁrst counting
area and systematically moved though all counting areas until
the entire delineated area was sampled. Actual counting was
performed using a 340 oil objective lens. Guard volumes (4
lm from the top and 4–6 from the bottom of the section)
were excluded from both surfaces to avoid the problem of lost
cap, and only the proﬁles that came into focus within the
counting volume (with a depth of 10 lm) were counted. The
total number of stained cells was calculated according to the
optical fractionator formula. To measure striatal density,
images of DARPP immunostaining in the striatum were cap-
tured. The numbers of DARPP-positive cells per mm2 were
measured using ImageGauge. For quantitative measure of apo-
ptosis in the frontal cortex, it was deﬁned as a percentage of
Annexin V-positive cells per total number of NeuN-positive
cells.
Statistical Analysis
Comparisons between groups were made using Student’s t tests
(paired) or one-way analysis of variance followed by a Dunnett
post-hoc tests. p Values less than .05 were considered statistically
signiﬁcant. Data were expressed as mean standard deviation. Sta-
tistical analyses were performed using commercially available soft-
ware (version 10.0; SPSS, Inc., Chicago, IL).
RESULTS
Characterization of hMSCs
FACS analysis conﬁrmed that the hMSCs obtained for this study
expressed CD29, CD44, CD73, CD105, and CD90, which are posi-
tive markers for hMSCs (Fig. 1A). Furthermore, hMSCs did not
express CD34, CD 45, and HLA-DR, which are negative markers for
hMSCs (Fig. 1B).
The First Experiment
Evaluation of ICA Flow and Cerebral Ischemia Following Intra-
Arterial Injection of MSCs. To evaluate ICA patency that might
be inﬂuenced by intra-arterial administration of MSCs, an ultra-
sonic ﬂow meter was used to measure blood ﬂow through the
ICA. The ICA blood ﬂow was well preserved in animals receiving a
310 of the standard dose of MSCs (Fig. 2A). In addition, to evalu-
ate any delayed adverse effect of ICA occlusion, we performed
MRI 4 weeks after MSC administration. No occlusive lesion of the
ICA was observed at a 310 of the standard dose (Fig. 2B). Using
T2-weighted MRI to detect ischemic brain lesions, no hyperin-
tense signals were observed in the brain of animals receiving a
310 of the standard dose (Fig. 2C). At the 350 of the standard
dose of MSCs, no animals survived more than 1 day after intra-
arterial MSC administration because MSCs were regurgitated
from the injection site of the ICA with concomitant bleeding.
Histological and Behavioral Analysis. Immunohistochemical
analysis revealed that MSA animals receiving double toxins
showed a signiﬁcant reduction of TH-positive and DARPP-32-
positive neurons in the SN and striatum compared with control
animals (Fig. 2D). Compared with MSA animals receiving placebo,
MSA animal receiving a 310 of the MSC standard dose in MSA
animals led to a signiﬁcant attenuation of TH-positive and DARPP-
32-positive neurons in the SN and striatum (Fig. 2D). We did not
perform immunohistochemical analysis in MSA animals receiving
a 350 of the standard dose of MSCs because of subject death
Figure 3. Evaluation of internal carotid artery (ICA) ﬂow and cerebral ischemia following intra-arterial injection of different doses of MSCs.
(A): An ultrasonic ﬂow meter showed that the ICA blood ﬂow was well preserved in animals receiving 30.2, 32, or 320 of the standard
dose. (B): Magnetic Resonance-angiography showed that no occlusive lesion of the ICA was observed at any of the MSC standard doses. (C):
T2*-weighted magnetic resonance imaging revealed that multiple system atrophy animals receiving a 320 of the standard dose of MSCs
exhibited high signal intensity in the middle cerebral artery territory (arrows). Abbreviation: MSC, mesenchymal stem cell.
1428 Mesenchymal Stem Cells in MSA
Oc 2017 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
STEM CELLS TRANSLATIONAL MEDICINE
from intra-arterial MSC administration. On behavioral analysis, the
number of rotations after apomorphine injection was signiﬁcantly
increased in double toxin-induced MSA animals compared with
control animals (Fig. 2E). However, MSA animals receiving a 310
of the standard dose of MSCs exhibited a signiﬁcant reduction in
rotation behavior 1 week after MSC treatment compared with
MSA animals receiving placebo (Fig. 2E).
The Second Experiment
Evaluation of ICA Flow and Cerebral Ischemia Following Intra-
Arterial Injection of Different Doses of MSCs. To evaluate efﬁ-
cacy of intra-arterially injected MSCs, we chose30.2,32, or320
of the standard dose that was individual dose below 310 of the
standard dose or between 310 and 350 of the standard dose of
MSCs. The ICA blood ﬂow evaluated by an ultrasonic ﬂow meter
was well preserved in animals receiving the 30.2, 32, and 320
of the standard doses of MSCs (Fig. 3A). In addition, no occlusive
lesion of the ICA was observed at any of the MSC standard doses
on MR-angiography (Fig. 3B). On T2*-weighted MRI, no hyperin-
tense signals were observed in the brain parenchymal of animals
receiving a 30.2 and 32 of the standard doses. However, MSA
animals receiving a 320 of the standard dose of MSCs exhibited
high signal intensity in the middle cerebral artery territory (Fig.
3B) without hemorrhagic lesions.
Histological and Behavioral Analysis. Immunohistochemical
analysis showed that MSC treatment with a 30.2 or 32 of the
standard dose in MSA animals led to a signiﬁcant increment of
Figure 4. Histological and behavioral analysis following intra-arterial injection of different doses of MSCs. (A, B): Immunohistochemical anal-
ysis showed that MSC treatment with a 30.2, 32, or 320 of the standard dose in MSA animals exhibited a signiﬁcant increment of TH- and
DARPP-32-positive neurons in the SN and striatum compared with MSA animals receiving placebo. A direct comparison revealed that prosur-
vival effect on TH-positive and DARPP-32-positive neurons was higher in MSA animals receiving a 32 of the standard dose compared with
those receiving a 30.2 or 320 of the standard dose (each group, n5 5). Scale bar represents 200 mm. (C): Behavioral analysis showed that
MSA animals receiving MSCs at 30.2 and 32 concentrations of the standard dose exhibited a signiﬁcant reduction in rotation behavior after
apomorphine injection compared with MSA animals receiving placebo or 320 of the standard dose of MSCs. (each group, n5 10). The data
are presented as the means6 SE. *, p< .05; **, p< .01. Abbreviations: DARPP-32, dopamine- and cAMP-regulated neuronal phosphoprotein;
MSA, multiple system atrophy; MSC, mesenchymal stem cell; 6-OHDA, 6-hydroydopamine; QA, quinolinic acid; TH, tyrosine hydroxylase.
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Figure 5. Intracerebral concentrations of MSCs. (A): In vivo imaging system analysis showing serial changes of ﬂuorescent signal intensity in
the brain following intra-arterial (IA) injection of a 310 standard dose. (B): NuMA-positive MSCs comerged with nanoparticle in the SN and
STR 8 weeks after intra-arterial administration. Scale bar represents 10 mm (C): Distribution patterns of MSCs in the brain depending on MSC
dose. Fluorescent signal intensity in the brain 1 day after IA administration exhibited an incremental tendency as the concentration of MSCs
was increased. Following intravenous administration of a 310 of the standard, ﬂuorescent signal intensity density in the brain was lower
than intra-arterial injection of a30.2 of the standard dose. Abbreviations: SN, substantia nigra; STR, striatum.
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TH-positive and DARPP-32-positive neurons in the SN and stria-
tum compared with MSA animals receiving placebo (Fig. 4A, 4B).
In direct comparison, the number of TH-positive and DARPP-32-
positive neurons was signiﬁcantly higher in MSA animals receiving
a32 of the standard dose compared with those receiving a30.2
of the standard dose (Fig. 4A, 4B). In MSA animals receiving a
320 of the standard dose of MSCs, the number of TH-positive
and DARPP-32-positive neurons was signiﬁcantly higher compared
with those receiving placebo. However, the prosurvival effect on
TH-positive and DARPP-32-positive neurons in MSA animals
receiving a 320 of the standard dose was inferior to a 32 of the
standard dose (Fig. 4A, 4B). In addition, MSC treatment with a
30.2,32, or320 of the standard dose in MSA animals decreased
signiﬁcantly Annexin V-positive cells in the frontal cortex com-
pared with MSA animals receiving placebo. Anti-apoptotic effect
was prominent in MSA animals receiving a 32 of the standard
dose compared with those receiving a 30.2 or 320 of the stand-
ard dose (Supporting Information Fig. S1). Behavioral analysis
showed that MSA animals receiving MSCs at 30.2 and 32 con-
centrations of the standard dose exhibited a signiﬁcant reduction
in rotation behavior 1 week after MSC treatment compared with
MSA animals receiving placebo (Fig. 4C). In a direct comparison,
there were no signiﬁcant differences in rotation behavior between
the 30.2 and 32 of the standard dose of MSCs at each post-
treatment time (Fig. 4C). However, the number of rotations after
apomorphine injection in MSA animals receiving a 320 of the
standard dose did not differ signiﬁcantly compared with placebo-
treated MSA animals (Fig. 4C).
Intracerebral Concentrations of MSCs. First, we examined
how long MSCs would survive in the brain following intra-arterial
injection of MSCs at a 310 standard dose. IVIS analysis showed
that the distribution of MSCs in the brain gradually decreased over
time, and 8 weeks after MSC injection, ﬂuorescent signal intensity
in the brain was markedly attenuated (Fig. 5A). Additionally,
NuMA-positive MSCs comerged with nanoparticle were identiﬁed
in the SN and striatum 8 weeks after intra-arterial administration
(Fig. 5B). Next, we evaluated distribution patterns of MSCs in the
brain depending on MSC dose. As expected, the distribution of
MSCs in the brain 1 week after intra-arterial administration had an
incremental tendency as the concentration of MSCs was increased
(Fig. 5C). Finally, we used intravenous injection of MSCs to evalu-
ate whether intracerebral concentrations of MSCs might differ
depending on delivery routes. When MSCs were administrated at
a 310 of the standard dose via the tail vein, ﬂuorescent signal
intensity density in the brain was even lower than intra-arterial
injection of a30.2 of the standard dose (Fig. 5C).
DISCUSSION
The present study revealed that if their concentration is appropri-
ate, intra-arterial injection of MSCs is safe and exerts a neuropro-
tective effect on striatal and nigral neurons with a coincidental
improvement in motor behavior. However, in addition to the fatal
effect of an extremely high MSC dose, intra-arterial injection of a
higher dose of MSCs led to the development of ischemic lesions
and thus attenuated improvement of behavioral performance.
Furthermore, IVIS analysis showed that intra-arterial injection of
MSCs increases cellular density in the brain compared with intra-
venous injection. These data indicate that intra-arterial
administration of MSCs is feasible and efﬁcacious with respect to
neuronal viability and behavioral performance in double toxin-
induced MSA models.
In terms of the pathogenesis of MSA, some clues to under-
standing the mechanisms of MSA have been suggested. Using
MSA transgenic mice, studies have suggested that mitochondrial
inhibitors or proteasome inhibitors might trigger or aggravate
MSA pathologies [18, 19]. Taken together, dysfunction in cellular
clearing systems and neuroinﬂammation may cause further dete-
rioration of these neurodegenerative processes [20]. Until now,
many clinical trials have been performed to uncover the efﬁcacy
of various treatments in patients with MSA; however, these trials
have failed to provide ample evidence of neuroprotection or had
limited efﬁcacy in MSA patients [21]. These results imply that if a
certain molecular candidate is to achieve a neuroprotective effect
in MSA patients, this candidate may need to fully prevent cell
death cascades in every pathogenic step.
With the idea that MSCs may have pleiotropic effects against
the neurodegenerative microenvironment, the present study
used a double-toxin-induced animal model of MSA to examine
the feasibility and efﬁcacy of intra-arterial administration of vari-
ous doses of MSCs to extend its clinical application to patients
with MSA. In the present study, a concentration of MSCs that
was used in previous clinical trials (4 3 107 MSCs) was selected
as a standard concentration. We found that MSA animals only
receiving 30.2 or 32 of the standard dose of MSCs exhibited
behavioral improvement relative to the placebo-treated group,
whereas prosurvival effects of MSCs in immunohistochemical
analysis were evident in MSA animals receiving 30.2, 32, or
320 of the standard dose. In a comparative analysis among MSC
treatment subgroups, behavioral analysis showed no signiﬁcant
difference in motor performance between MSA animals receiving
30.2 and32 of the standard dose; however, immunohistochem-
ical analysis demonstrated that prosurvival effects on striato-
nigral neurons were more prominent in MSA animals receiving
the 32 of the standard dose compared with those receiving a
30.2 or 320 of the standard dose. Therefore, combining behav-
ioral and histological analyses, the present data indicate that a
32 of the standard dose of MSCs may be the most efﬁcacious
dose of intra-arterial injection in MSA animals.
We also found that intra-arterial administration of higher
doses of MSCs led to in situ occlusion of the injected artery or
ischemic insults in the distal cerebral arterial circulation. Speciﬁ-
cally, when MSA animals were injected with a 350 of the stand-
ard dose, the cells were regurgitated from the injection site in the
ICA probably due to arterial occlusion, which led to higher mortal-
ity. In addition, intra-arterial injection with a 320 of the standard
dose was associated with ischemic lesions in the distal MCA terri-
tory. This may explain why MSA animals receiving the 320 of the
standard dose of MSCs did not show a signiﬁcant improvement in
behavioral performance and neuronal survival compared with
those receiving a 30.2 or 32 of the standard dose. In terms of
ischemic complication associated with intra-arterial injection of
MSCs, cell dose, and patency of arterial ﬂow are important factors
in determining the development of ischemic insults, even though
the complication rate appears to vary depending on the experi-
mental design of intra-arterial injection [14, 15, 22]. Additionally,
our previous clinical studies demonstrate that the frequency of
ischemic insults is comparable between MSC-treated and
placebo-treated groups, suggesting that ischemic lesions seem to
be a consequence of the angiographic procedure rather than
intra-arterial MSC injection. Accordingly, the present study
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provides further in vivo evidence that if arterial ﬂow is patent dur-
ing intra-arterial administration, the cellular density of MSCs
around a standard dose is quite safe and free from ischemic
insults in addition to providing neuroprotective efﬁcacy. However,
because we did not determine the infusion volume or infusion
velocity as a contributing factor to the development of cerebral
ischemia [23]. A further study would be required to resolve safety
issues related with intra-arterial injection of MSCs.
IVIS analysis showed that intra-arterial injection of MSCs
markedly increased migration of MSCs into the brain compared
with intravenous injection. MSCs characteristically migrate toward
injured brain areas in various animal models of ischemia and Par-
kinson’s disease, possibly in response to signals that are upregu-
lated under injury conditions [24, 25]. SDF-1 is widely expressed in
the brain, including the cortex, cerebellum, basal ganglia, and SN
pars compacta [25]. Damage in the SN and striatum induced by 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 3-NP may
increase the expression of SDF-1 and CXCR4, leading to recruit-
ment of MSCs to these regions. As expected, the present study
showed that the distribution of intra-arterially injected MSCs in
the brain had an incremental tendency as the concentration of
MSCs was increased. Together, we directly compared the tendency
of homing effects between intra-arterial and intravenous routes
by analyzing IVIS. The number of homing MSCs after intravenous
administration even at the310 of the standard dose of MSCs was
much lower than intra-arterial injection of a30.2 of the standard
dose. As these migrated cells may contribute to modulation of the
microenvironmental cascade of the neurodegenerative process in
the brain, the intra-arterial route would be by far superior to the
intravenous route in terms of bioavailability of homing MSCs.
Finally, we found that when a310 dose of MSCs was adminis-
trated via the intra-arterial route, the concentration of MSCs in
the brain gradually decreased over time, and 8 weeks after MSC
injection, the cellular signal intensity in the brain was markedly
attenuated. Considering the survival time of MSCs, this may raise
the possibility of the need for additional MSC administrations to
bolster homing MSCs. Similarly, our previous clinical trial demon-
strates that the neuroprotective effect of MSCs tend to fade away
around day 240 after the ﬁrst intra-arterial MSC injection, imply-
ing repeated administration of MSCs may be needed to maintain
their neuroprotective properties [10]. However, further studies
determining the most appropriate time interval of repetitive MSC
administrations are required for clinical application in patients
with MSA.
CONCLUSION
Our study has provided important details that intra-arterial admin-
istration of MSCs is feasible and efﬁcient administration route,
resulting in improvement of neuronal viability and behavioral per-
formance in double toxin-induced MSA models. The present data
may advance clinical applications of intra-arterial route of MSC
administration in patients with MSA.
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